GlassScriptPhysician profile
Yinghui Liu
NPI 1003025271
$8,014.28
in general payments reported to CMS, 2019-2025
41 companies · $1,269 in 2025
The $1,269 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $631 · 2020: $972 · 2021: $1,245 · 2022: $1,523 · 2023: $1,341 · 2024: $1,034 · 2025: $1,269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,644.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,284.46 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $665.88 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $568.88 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $564.43 | 2021-2025 | |
| Gilead Sciences, INC. | $488.36 | 2021-2025 | |
| Glaxosmithkline, LLC. | $460.02 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $445.68 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $373.00 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $349.19 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $304.29 | 2019-2023 | Steglatro, Belsomra |
| Pfizer INC. | $296.14 | 2019-2025 | |
| Exact Sciences Corporation | $255.51 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $227.24 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $222.86 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $218.24 | 2022-2024 | Quviviq |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yinghui Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.